Commercialisation Of Biosimilars: Strategies For Market Penetration

Based on expert opinions from the top commentators in the field, the report offers insight into how European biosimilar markets have evolved. It also includes up to the minute US case studies, insight into specific approaches to biosimilars intended for multiple diseases and which strategies have proven most effective-and why. Learn more here. (Source: FirstWord, 11/2013).

You might also be interested in:

IQVIA Report Looks at Biosimilars in EU September 10, 2018
Biosimilars: US Payer Perspectives April 19, 2018
Health Economist Issues Warning on Biosimilar Savings March 7, 2018
Orphan Drugs: European Payer Perspectives October 14, 2018
Biosimilars: E.U. Payer Perspectives February 23, 2018
FDA Green Lights First Epoetin Alfa Biosimilar for Anemia May 16, 2018
Article Touts RWE as Boon to Biosimilars, Special Populations September 6, 2018